THE MECHANISMS OF HEART FAILURE DEVELOPMENT IN OBESITY
https://doi.org/10.15829/1560-4071-2018-5-81-86
Abstract
The epidemic of obesity impacts significantly the prevalence of cardiovascular diseases, including heart failure. Obesity facilitates proinflammatory status onset, that leads to changes in metabolism of free fatty acids, lipids, glucose, influencing myocardial function and heart failure progression from diastolic to systolic. Also, there is data confirming influence of obesity on central and peripheral hemodynamics. To understand these mechanisms is necessary for development of prevention activities against chronic heart failure and other cardiovascular events.
About the Authors
O. V. Gritsenko
Altaiskiy Kray Cardiological Dispensary
Russian Federation
Barnaul
Russian Federation
Barnaul
G. A. Chumakova
Altaiskiy State Medical University of the Ministry of Health;
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Barnaul, Kemerovo
Russian Federation
Barnaul, Kemerovo
I. V. Shevlyakov
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Kemerovo
Russian Federation
Kemerovo
E. V. Trubina
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Kemerovo
Russian Federation
Kemerovo
References
1. Lakomkin VS, Skvortsov AA, Goryunov TV, et al. Galectin-3 — a new marker of diagnosis and prognosis of chronic heart failure. Cardiology 2012; 3 (52): 45-52. (In Russ.)
2. Gamgan KA, Drapkina OM, Maksimov ML. Galectin-3: clinical and prognostic value of determination in patients with chronic heart failure. Rus Heart Failure J 2014; 82 (1): 51-5. (In Russ.).
3. Bombelli M, Facchetti R, Fodri D, et al. Impact of body mass index and waist circumference on the cardiovascular risk and all-cause death in a general population: data from the PAMELA study. Nutr Metab Cardiovasc Dis 2012; 2013; 23 (7): 650-6. DOI: 10.1016/j. numecd.2012.01.004.
4. Druzhilov MA, Druzhilova OYu, Kuznetsova TYu, et al. Obesity as cardiovascular risk factor: accent on quality and functional activity of adipose tissue. Russ J Cardiol 2015; 4: 111-7. (In Russ.)
5. Jindal A, Whaley-Connell A, Sowers JR. Obesity and heart failure as a mediator of the cerebrorenal interaction. Contrib Nephrol 2013; 179: 15-23. DOI: 10.1159/000346718.
6. Ebong IA, Goff DC, Rodriges CJ, et al. Mechanisms of Heart Failure in Obesity. Obes Res Clin Pract. 2014; 8 (6): 540-8. DOI: 10.1016/j.orcp.2013.12.005.
7. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925-32. DOI: 10.1016/j. jacc.2008.12.068.
8. Ashrafian H, leRoux CW, Darzi A, et al. Effects ofBariatricSurgeryon Cardiovascular Function. Circulation. 2008; 118 (20): 2091-102. DOI: 10.1161/CIRCULATIONAHA.107.721027.
9. Kim M, Oh JK, Sakata S, et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008; 45 (2): 270-80.
10. Dedov II, Alexandrov AA, Kukharenko SS. Heart and obesity. Obesity and metabolism 2006; 1: 14-20. (In Russ.)
11. Voulgari C, Tentolouris N, Dilaveris P, et al. Increased Heart Failure Risk in NormalWeight People With Metabolic Syndrome Compared With Metabolically Healthy Obese Individuals. J Am Coll Cardiol 2011; 58 (13): 1343-50. DOI: 10.1016/j.jacc.2011.04.047.
12. Chumakova GA, Veselovskaya NG. Clinical significance of visceral obesity. Moscow. GEOTAR-Media. 2016. 160. (In Russ.)
13. Druzhilov MA, Beteleva YE, Druzhilova OY, et al. The role of epicardial obesity in the development of structural and functional remodeling of the heart. Russ J Cardiol 2017; 4: 35-9. (In Russ.) DOI: 1015829/15604071-2017-4-35-39.
14. Astashkin EI, Glaser MG. Lipotoxic effects in the heart, observed in obesity. Arterial hypertension 2009; 15 (3): 335-41. (In Russ.)
15. Ritchie RH. Evidence for a causal role of oxidative stress in the myocardial complications of insulin resistance. Heart Lung Circ 2009; 18 (1): 11-8.
16. Nishida K, Otsu K. Inflammation and metabolic cardiomyopathy. Cardiovasc Res 2017; 113: 389-98. DOI: 10.1093/cvr/cvx012.
17. Oikonomou E, Tousoulis D, Siasos G, et al. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J. Cardiol 2011; 52 (1): 30-40.
18. Baguet J-P, Barone-Rochette G, Tamisier R, et al. Mechanisms of cardiac dysfunction in obstructive sleep apnea. Nat Rev Cardiol. 2012; 9 (12): 679-88. DOI: 101038/ nrcardio.2012.141.
19. Turer AT, Hill JA, Elmquist JK, et al. Adipose Tissue Biology and Cardiomyopathy. Translational Implications. Circ Res 2012; 111 (12): 1565-77. DOI: 101161/ CIRCRESAHA111.262493.
20. Horwich TB, Fonarow GC. Glucose, Obesity, Metabolic Syndrome, and Diabetes relevance to Incidence of Heart Failure. J Am Coll Cardiol 2010; 55 (4): 283-93. DOI: 101016/j. jacc.2009.07.029.
21. Voulgari C, Tentolouris N, Dilaveris P, et al. Increased Heart Failure Risk in NormalWeight People With Metabolic Syndrome Compared With Metabolically Healthy Obese Individuals. J Am Coll Cardiol 2011; 58 (13): 1343-50. DOI: 10.1016/j.jacc.2011.04.047.
22. Drosatos K, Schulze PC. Cardiac Lipotoxicity: Molecular Pathways and Therapeutic Implications. Curr Heart Fail Rep 2013; 10 (2): 109-21.
23. Veselovskaya NG, Chumakova GA, Kozarenko AA, et al. Adipokines as the corrected risk factor of cardiovascular diseases. Russian journal of cardiology 2010; 6: 88-93. (In Russ.)
24. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. Biochemical and Biophysical Research Communications 2012; 425 (3): 560-4.
25. Smith CCT, Yellon DM. Adipocytokines, cardiovascular pathophysiology and myocardial protection.Pharmacol Ther 2011; 129 (2): 206-19. DOI: 101016/j.pharmthera.2010.09.003.
26. Symons JD, Abel ED. Lipotoxicity contributes to endothelial dysfunction: A focus on the contribution from ceramide. Rev Endocr Metab Disord. 2013; 14 (1): 59-68.
27. Nanayakkara G, Kariharan T, Wang L, et al. The cardio-protective signaling and mechanisms of adiponectin. Am J Cardiovasc Dis 2012; 2 (4): 253-66.
28. Mikityuk MR, Khizhnyak OO. The Role of leptin in the formation of left ventricular hypertrophy in patients with acromegaly. Scientific Bulletin Series Medicine. Pharmacy 2014; 18 (189): 111-8. (In Russ.)
29. Travers JG, Kamal FA, Robbins J, et al. Cardiac Fibrosis: The Fibroblast Awakens. Circ Res 2016; 118 (6): 1021-40. DOI: 10.1161/CIRCRESAHA115.306565.
30. Wang J, Bo Xiang, Hung-Yu Lin, et al. Pathological Mechanism for Delayed Hyperenhancement of Chronic Scarred Myocardium in Contrast Agent Enhanced Magnetic Resonance Imaging. PloS One 2014; 9(5): e96463. DOI: 10.1371/journal. pone.0096463
31. Ban CR, Twigg SM. Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag 2008; 4 (3): 575-96.
32. Mewton N, Ying LC, Pierre С, et al. Assessment of Myocardial Fibrosis with Cardiac Magnetic Resonance. J Am Coll Cardiol 2011; 57 (8): 891-903.
33. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010; 11: 31-9.
34. Berezin AE. Systolic and diastolic heart failure: two sides of the same process? Review. Ukrainian medical journal actual issues of clinical practice 2014; 3 (101): 91-6. (In Russ.)
35. Kwon DH, Halley CM, Popovic ZB, et al. Gender differences in survival in patients with severe left ventricular dysfunction despite similar extent of myocardial scar measured on cardiac magnetic resonance. Eur J Heart Fail 2009; 11: 937-44.
Review
For citations:
Gritsenko O.V., Chumakova G.A., Shevlyakov I.V., Trubina E.V. THE MECHANISMS OF HEART FAILURE DEVELOPMENT IN OBESITY. Russian Journal of Cardiology. 2018;(5):81-86. (In Russ.) https://doi.org/10.15829/1560-4071-2018-5-81-86
Views:
2226
Email this article 